[go: up one dir, main page]

WO1998042650A3 - Leukotriene antagonists useful for treating cystic fibrosis - Google Patents

Leukotriene antagonists useful for treating cystic fibrosis Download PDF

Info

Publication number
WO1998042650A3
WO1998042650A3 PCT/US1998/005455 US9805455W WO9842650A3 WO 1998042650 A3 WO1998042650 A3 WO 1998042650A3 US 9805455 W US9805455 W US 9805455W WO 9842650 A3 WO9842650 A3 WO 9842650A3
Authority
WO
WIPO (PCT)
Prior art keywords
cystic fibrosis
leukotriene antagonists
treating cystic
antagonists useful
leukotriene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/005455
Other languages
French (fr)
Other versions
WO1998042650A2 (en
Inventor
Jerome H Fleisch
William T Jackson
Jason S Sawyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to AU67647/98A priority Critical patent/AU6764798A/en
Publication of WO1998042650A2 publication Critical patent/WO1998042650A2/en
Publication of WO1998042650A3 publication Critical patent/WO1998042650A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention provides methods for the treatment or inhibiting of the symptoms of cystic fibrosis which comprises administering to a mammal in need thereof an effective amount of a compound having activity as a leukotriene B4 antagonist.
PCT/US1998/005455 1997-03-21 1998-03-19 Leukotriene antagonists useful for treating cystic fibrosis Ceased WO1998042650A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU67647/98A AU6764798A (en) 1997-03-21 1998-03-19 Leukotriene antagonists useful for treating cystic fibrosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4087097P 1997-03-21 1997-03-21
US60/040,870 1997-03-21

Publications (2)

Publication Number Publication Date
WO1998042650A2 WO1998042650A2 (en) 1998-10-01
WO1998042650A3 true WO1998042650A3 (en) 1998-12-23

Family

ID=21913422

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/005455 Ceased WO1998042650A2 (en) 1997-03-21 1998-03-19 Leukotriene antagonists useful for treating cystic fibrosis

Country Status (2)

Country Link
AU (1) AU6764798A (en)
WO (1) WO1998042650A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127882A1 (en) 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
JP2001247459A (en) 2000-03-03 2001-09-11 Oakland Uniservices Ltd Cancer combination therapy
AU2001282717A1 (en) 2000-07-28 2002-02-13 Cancer Research Technology Limited Cancer treatment by combination therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2007307597A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
US5543428A (en) * 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors
US5552441A (en) * 1992-12-10 1996-09-03 Eli Lilly And Company Leukotriene B4 antagonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists
US5552441A (en) * 1992-12-10 1996-09-03 Eli Lilly And Company Leukotriene B4 antagonists
US5478857A (en) * 1993-12-23 1995-12-26 Eli Lilly And Company Use of PLA2 inhibitors as treatment for alzheimer's disease
US5563164A (en) * 1993-12-23 1996-10-08 Eli Lilly And Company Phospholipase A2 inhibitors
US5543428A (en) * 1994-08-31 1996-08-06 Eli Lilly And Company Method for treating resistant tumors

Also Published As

Publication number Publication date
WO1998042650A2 (en) 1998-10-01
AU6764798A (en) 1998-10-20

Similar Documents

Publication Publication Date Title
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
HUP0004412A3 (en) Use of heterocyclic vinylethers for the preparation of pharmaceutical compositions treating neurological disorders
HK1038755A1 (en) Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
AU4025599A (en) Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
BG104177A (en) Amlodipin- and atorvastatin-containing therapeutical combinations
CA2311356A1 (en) Method for treating alzheimer's disease
IL135951A0 (en) Antimutagenic compositions for the treatment and prevention of photodamage to skin
ZA977783B (en) Method of inhibiting fibrosis with a somatostatin agonist
EA200000012A1 (en) COMBINATION THERAPY, INCLUDING ATORVASTATIN AND ANTIHYPERTENSIVE AGENT
WO2001015678A3 (en) Topical use of kappa opioid agonists to treat otic pain
WO2001036365A3 (en) Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
AU2001247474A1 (en) Compounds for the treatment of psychiatric or substance abuse disorders
WO2004050030A3 (en) Anti-sickling agents
ID20637A (en) METHODS FOR INHIBITING THE FORMATION OF BIOGENIC SULFIDA
EP0742010A3 (en) Benzoquinolin-3-ones to inhibit bone loss
WO1999005096A3 (en) Urokinase inhibitors
WO2000077206A3 (en) The myostatin gene promoter and inhibition of activation thereof
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
WO2000061069A3 (en) Methods and compositions for use in the treatment of hyperlipidemia
ZA9811507B (en) Combination effective for the treatment of impotence.
CA2338066A1 (en) Treatment of dyskinesia
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
EP1032556A4 (en) Pharmaceutically active compounds and methods of use
WO1998042650A3 (en) Leukotriene antagonists useful for treating cystic fibrosis
WO1998026770A3 (en) The topical use of kappa opioid agonists to treat ocular pain

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998545814

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA